Skip to main navigation Skip to search Skip to main content

Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors

Research output: Contribution to journal › Article › peer-review

Abstract

The prognosis for many pediatric and young adult patients with solid tumors that have metastasized at the time of diagnosis or have relapsed after therapy remains very poor. The steep dose-response curve of many of these tumors to alkylating agents makes myeloablative chemotherapy followed by autologous stem cell transplantation (ASCT) an attractive potential therapy. The role of ASCT for these high-risk patients is yet to be conclusively determined. We have transplanted 36 patients on two consecutive protocols with a variety of histological diagnoses. Overall survival (OS) was 63% (95% CI: 47-79%) at 1 year and 33% (95% CI: 16-50%) at 3 years. Patients with a diagnosis of Ewing's sarcoma (ES) or desmoplastic small round cell tumor (DSRCT) had significantly better survival than those with other diagnoses with estimated 3-year OS of 54% (95% CI: 29-79%) for this group of patients (P = 0.03). There were two transplant-related deaths both attributable to hepatic veno-occlusive disease. Median follow-up among survivors is 3.5 years (range: 0.6-7.9 years). These data justify continued investigation of ASCT as a consolidation therapy in patients with metastatic or relapsed ES and DSRCT.

Original languageEnglish (US)
Pages (from-to)175-181
Number of pages7
JournalBone marrow transplantation
Volume37
Issue number2
DOIs
StatePublished - Jan 2006

Bibliographical note

Funding Information:
This work was supported in part by a grant from the Children’s Cancer Research Fund.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Autologous stem cell transplantation
  • Ewing's sarcoma
  • Pediatric solid tumors

Fingerprint

Dive into the research topics of 'Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors'. Together they form a unique fingerprint.

Cite this